Immunopharmacological activities of the nontoxic monophosphoryl lipid a of Porphyromonas gingivalis

Vaccine

Volumn 14, Issue 1, 1996, Pages 70-76

  Ogawa, Tomohiko ^a   Nakazawa, Mitsuhiro ^a   Masui, Kyoko ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Antitumour activity; Porphyromonas gingivalis lipid A; Sepsis

Indexed keywords

LIPID A;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; HOST RESISTANCE; IMMUNE RESPONSE; IMMUNOPHARMACOLOGY; INTRADERMAL DRUG ADMINISTRATION; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PORPHYROMONAS; PRIORITY JOURNAL; SALMONELLA; SEPSIS; SPLEEN CELL;

EID: 0030041104     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(95)00128-N     Document Type: Article

References (32)

1. Kusumoto, S. Chemical syhthesis of lipid A. In: Bacterial Endotoxic Lipopolysaccharides (Eds Morrison, D.C. and Ryan, J.L.). CRC Press, New York, 1992, pp. 81-105
2. Takada, H. and Kotani, S. Structure-function relationships of lipid A. In: Bacterial Endotoxic Lipopolysaccharides (Eds Morrison, D.C. and Ryan, J.L.). CRC Press, New York, 1992, pp. 107-134
3. Rietschel, E.T., Brade, H., Brade, L. et al. Lipid A, the endotoxic center of bacterial lipopolysaccharides: relation of chemical structure to biological activity. Prog. Clin. Biol. Res. 1987, 231, 25-53
4. Homma, J.Y., Matsuura, M. and Kumazawa, Y. Studies on lipid A, the active center of endotoxin - structure - activity relationship. Drugs Future 1989, 4, 645-665
5. von Eschen, K.B. Monophosphoryl lipid A and immunotherapy. In: Bacterial Endotoxic Lipopolysaccharides (Eds Morrison, D.C. and Ryan, J.L). CRC Press, New York, 1992, pp. 411-428
6. Nakatsuka, M., Kumazawa, Y., Matsuura, M., Homma, J.Y., Kiso, M. and Hasegawa, A. Enhancement of nonspecific resistance to bacterial infections and tumor regressions by treatment with synthetic lipid A-subunit analogs. Critical role of 4-O-phophono-D-glucosamine derivatives. Int. J. Immunopharmacol. 1989, 11, 349-358
7. Lam, C., Schütze, E., Hildebrandt, J., Aschauer, H., Liehl, E., Macher, I. and Stütz, P. SDZ MRL 953, a novel immunostimulatory monosaccharidic lipid A analog with an improved therapeutic window in experimental sepsis. Antimicrob. Agents Chemother. 1991, 35, 500-505
8. Slots, J. and Listgarten, M.A. Bacteroides gingivalis, Bacteroides intermedius and Actinobacillus actinomycetemcomitans in human periodontal diseases. J. Clin. Periodontol. 1988, 15, 85-93
9. Ogawa, T. Chemical structure of lipid A from Porphyromonas (Bacteroides) gingivalis lipopolysaccharide. FEBS Lett. 1993, 332, 197-201
10. Ogawa, T. Immunobiological properties of chemically defined lipid A from lipopolysaccharide of Porphyromonas (Bacteroides) gingivalis. Eur. J. Biochem. 1994, 219, 737-742
11. Ogawa, T., Uchida, H. and Amino, K. Immunobiological activities of chemically defined lipid A from lipopolysaccharides of Porphyromonas gingivalis. Microbiology 1994, 140, 1209-1216
12. Westphal, O. and Jann, K. Extraction with phenol and further applications of the procedure. Meth. Carb. Chem. 1965, 5, 83-91
13. Dittmer, J.C. and Lester, R.L. A simple, specific spray for the detection of phospholipids on thin-layer chromatograms. J. Lipid Res. 1964, 5, 126-127
14. Fischer, F.G. and Dörfel, H. Die quantitative bestimmung reduzierender zucker auf papierchromatogrammen. Hoppe-Seyler's Z. physiol. Chem. 1954, 297, 164-178
15. Ogawa, T., Shimauchi, H., Furuta, R., Kawata, S., Yokogawa, K. and Kotani, S. Oral immunoadjuvant of lipophilic derivatives of N-acetylglucosaminyl-β(1→4)-N-acetylmuramyl-L-alanyl-D-isoglutaminyl- (L)-2, 6-meso-diaminopimeric acid-(D)-amide. Vaccine 1995, 13, 887-889
16. Ogawa, T., Kusumoto, Y., Uchida, H., Nagashima, S., Ogo, H. and Hamada, S. Immunobiological activities of synthetic peptide segments of fimbrial protein from Porphyromonas gingivalis. Biochem. Biophys. Res. Commun. 1991, 180, 1335-1341
17. Jacobs, D.M. and Morrison, D.C. Inhibition of the mitogenic response to lipopolysaccharide (LPS) in mouse spleen cells by polymyxin B. J. Immunol. 1977, 118, 21-27
18. Ogawa, T. The potential protective immune responses to synthetic peptides containing conserved epitopes of Porphyromonas gingivalis fimbrial protein. J. Med. Microbiol. 1994, 41, 349-358
19. Koga, T., Nishihara, T., Fujiwara, T., Nisizawa, T., Okahashi, N., Noguchi, T. and Hamada, S. Biochemical and immunobiological properties of lipopolysaccharide (LPS) from Bacteroides gingivalis and comparison with LPS from Escherichia coli. Infect. Immun. 1985, 47, 638-647
20. Joiner, K.A., Keith, P.W., McAdam, W.J. and Kasper, D.L. Lipopolysaccharides from Bacteroides fragilis are mitogenic for spleen cells from endotoxin responder and nonresponder mice. Infect. Immun. 1982, 36, 1139-1145
21. Kumada, H., Watanabe, K., Umemoto, T., Haishima, Y. Kondo, S. and Hisatsune, K. Occurrence of O-phosphorylated 2-keto-3-deoxyoctonate in the lipopolysaccharide of Bacteroides gingivalis. FEMS Microbiol. Lett. 1988, 51, 77-80
22. Fujiwara, T., Ogawa, T., Sobue, S and Hamada, S. Chemical, immunobiological and antigenic characterizations of lipopolysaccharides from Bacteroides gingivalis strains. J. Gen. Microbiol. 1990, 136, 319-326
23. Danner, R.L., Suffredini, A.F., Natanson, C. and Parrillo, J.E. Microbial toxins: role in the pathogenesis of septic shock and multiple organ failure. In: Multiple Organ Failure (Eds Bihari, D.J. and Cerra, RB.). Society of Critical Care Medicine, Fullerton, 1989, pp. 151-191
24. Corriveau, C.C. and Danner, R.L. Endotoxin as a therapeutic target in septic shock. Infect. Agents Dis. 1993, 2, 35-43
25. Ogawa, T., McGhee, M. L., Moldoveanu, Z., Hamada, S., Mestecky, J., McGhee, J.R. and Kiyono, H. Bacteroides-specific IgG and IgA subclass antibody-secreting cells isolated from chronically inflamed gingival tissues. Clin. Exp. Immunol. 1989, 76, 103-110
26. Ogawa, T., Kusumoto, Y., Hamada, S., McGhee, J.R. and Kiyono, H. Bacteroides gingivalis-specific serum IgG and IgA subclass antibodies in periodontal diseases. Clin. Exp. Immunol. 1990, 82, 318-325
27. Young, L., Meyer, R. and Armstrong, D. Pseudomonas aeruginosa vaccine in cancer patients. Ann. Intern. Med. 1973, 79, 518-527
28. Kim, Y. and Watson, D. Modification of host responses to bacterial endotoxins. II. Passive transfer of immunity to bacterial endotoxin with fractions containing 19S antibodies. J. Exp. Med. 1965, 121, 751-759
29. Dunn, D., Bogard, W. and Cerra, F. Enhanced survival during murine gram-negative sepsis by use of a murine monoclonal antibody. Arch. Surg. 1985, 120, 50-53
30. Johnson, A.G., Tomai, M., Solem, L., Beck, L. and Ribi, E. Characterization of a nontoxic monophosphoryl lipid A. Rev. Infect. Dis. 1987, 9 (Suppl. 5), S512-S516
31. Livingston, P.O., Jones, M., Deleo, A.B., Oettgen, H.F. and Old, L.J. The serologic response to Meth A sarcoma vaccines after cyclophosphamide treatment is additionally increased by various adjuvants. J. Immunol. 1985, 135, 1505-1509
32. Mitchell, M.S., Kan-Mitchell, J., Kempf, R.A., Harel, W., Shau, H. and Lind, S. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. 1988, 48, 5883-5893